Cervical cancer and the SUS: Impact of the HPV vaccination campaign on cervical cancer treatment
O câncer de colo do útero e o SUS: Impacto da campanha de vacinação contra HPV no tratamento para o câncer cervical
Resumo
Cervical cancer (or cervical cancer) has been among the top five causes of cancer mortality in women worldwide and HPV infection is considered a necessary condition for the development of more than 90% of cervical cancer cases. of the uterus. The SUS provides treatments for malignant neoplasia of the cervix and, since 2014, has also provided tetravalent vaccines (against HPVs 6, 11, 16, and 18) and bivalent vaccines (against HPVs 16 and 18), as well as medications to treat anogenital warts. and cervical injuries. The objective of this work was to analyze the impact of the quadrivalent HPV vaccine on the services offered by the SUS for the treatment of cervical cancer. It was possible to observe a statistically significant relationship between the doses of the female HPV vaccine applied and the variations in treatments performed and also in the recorded diagnoses of malignant neoplasia of the cervix.
Downloads
Referências
BRASIL. Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Divisão de Detecção Precoce e Apoio à Organização de Rede. Diretrizes brasileiras para o rastreamento do câncer do colo do útero. – 2. ed. rev. atual. – Rio de Janeiro: INCA, 2016.
CROSBIE, E. M.; EINSTEIN, M. H.; FRANCESCHI, S.; KITCHENER, H. C. Human Papillomavirus and Cervical Cancer. Lancet. 382, 289-299, 2013.
DE VILLIERS, E-M. Cross-roads in the classification of papilomavíruses. Virology, 2013.
FERRAZ, L. C.; SANTOS, A. B. R.; DISCACCIATI, M. G. Ciclo celular, HPV e evolução da neoplasia intraepitelial cervical: seleção de marcadores biológicos. J. Health Sci. Inst, 2012.
Gastos Federais em Oncologia. Observatório de Oncologia, 2018. Disponível em: https://observatoriodeoncologia.com.br/gastos-federais-em-oncologia/. Acesso em: 02/10/2023.
INCA – Instituto Nacional do Câncer. Estimativa 2021: Incidência de câncer no Brasil. Rio de Janeiro: Ministério da Saúde. 2020.
JUNG, H. S.; RAJASEKARAN, N.; JU, W.; SHIN,. Y. K.; Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer. J. Clin. Med. 4, 1126-1155. 2015.
MUÑOZ, N.; BOSCH, F. X.; SANJOSÉ, S.; HERRERO, R.; CASTELLSAGUÉ, X.; SHAH, K.V.; SNIJDERS, P. J. F.; MEIJER, C. J. L. M. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med. 348:518-527, 2003.
PINTO, L.A.; DILLNER, J.; BEDDOWS, S.; UNGER, E.R. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine. 2018 Aug 6;36 (32 Pt A): 4792-4799.
RSTUDIO TEAM. RStudio: Integrated Development Environment for R. Boston, MA. Disponível em http://www.rstudio.com. Acesso em 30 de setembro de 2021.
SALINAS-MONTALVO, A. M.; SUPRAMANIAM, A.; MCMILLAN, N. A.; IDRIS, A. RNA-based gene targeting therapies for human papillomavirus driven cancers. Cancer Letters, 523, 111-120, 2021.
SANTOS, J. G. C. & DIAS, J. M. G. (2018). Vacinação pública contra o papilomavirus humano no Brasil. Rev Med Minas Gerais, 28(1), 1-7.
SILVEIRA, L. T.; CARDOSO, G. D. M.; LIMA, D. C.; TEIXEIRA, A. M.; de OLIVEIRA KRAUSS, G. P.; da CRUZ RAMOS, M. L. C. & de PÁDUA NOGUEIRA, M. (2022). Avaliação dos custos relacionados às medidas preventivas e ao tratamento do câncer de colo de útero no Brasil. Brazilian Journal of Health Review, 5(2), 6550-6569.
WILD, C.P.; WEIDERPASS, E.; STEWART, B.W. editors (2020). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. Available from: http://publications.iarc.fr/586. Licence: CC BY-NC-ND 3.0 IGO.
